Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

Université Laval

$150,000.00

A novel blood biomarker to diagnose and predict evolution in Parkinson's disease

EF 2023-24

Résumé
Supervisor's name: Francesca Cicchetti Institution name: Université Laval Parkinson's disease (PD) is a complex brain disorder which typically manifests in adulthood with predominant motor (tremor, rigidity) symptoms. There is currently no cure for this disease nor efficient means by which to provide a rapid and accurate diagnosis. Moreover, diagnoses are preceded by a lengthy prodromal stage during which symptoms appear very slowly, many of which are barely noticeable or simply ignored as they are common to various non-threatening conditions (e.g., constipation). By the time patients consult with a specialist, a number of proteins have begun to misfold and malfunction, most vulnerable cells in the brain are already damaged beyond repair, and consequently, an interventional therapeutic window has closed. The identification of a biomarker - any measurable substance or signs associated with the disease - therefore offers one of the best hopes to provide tools for accurate diagnosis, predicting disease progression, and validating the efficacy of treatments. The latest research of Dr. Cicchetti's laboratory has focused on studying blood samples from PD patients and healthy controls. These studies revealed that extracellular vesicles produced by blood cells - small messenger packets released from most cells in the human body during sickness or health - are more abundant in PD patients and contain different combinations of proteins at different stages of the disease. This project proposal focuses on the validation of these results in large cohorts of patients to bring to commercialization a test that would be used in the clinic and by pharmaceutical companies.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
495697
Name
Cerquera-Cleves Catalina
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
A novel blood biomarker to diagnose and predict evolution in Parkinson's disease
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Biomarkers; Blood; Diagnostic Tool; Erythrocytes; Extracellular Vesicles; Parkinson'S Disease; Red Blood Cells
Abstract
Supervisor's name: Francesca Cicchetti Institution name: Université Laval Parkinson's disease (PD) is a complex brain disorder which typically manifests in adulthood with predominant motor (tremor, rigidity) symptoms. There is currently no cure for this disease nor efficient means by which to provide a rapid and accurate diagnosis. Moreover, diagnoses are preceded by a lengthy prodromal stage during which symptoms appear very slowly, many of which are barely noticeable or simply ignored as they are common to various non-threatening conditions (e.g., constipation). By the time patients consult with a specialist, a number of proteins have begun to misfold and malfunction, most vulnerable cells in the brain are already damaged beyond repair, and consequently, an interventional therapeutic window has closed. The identification of a biomarker - any measurable substance or signs associated with the disease - therefore offers one of the best hopes to provide tools for accurate diagnosis, predicting disease progression, and validating the efficacy of treatments. The latest research of Dr. Cicchetti's laboratory has focused on studying blood samples from PD patients and healthy controls. These studies revealed that extracellular vesicles produced by blood cells - small messenger packets released from most cells in the human body during sickness or health - are more abundant in PD patients and contain different combinations of proteins at different stages of the disease. This project proposal focuses on the validation of these results in large cohorts of patients to bring to commercialization a test that would be used in the clinic and by pharmaceutical companies.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cerquera-Cleves, Catalina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~